Immunotherapy in metastatic castration-resistant prostate cancer: transformative for the few, not for all.
0/5 보강
APA
de Souza VPB, Barata PC (2026). Immunotherapy in metastatic castration-resistant prostate cancer: transformative for the few, not for all.. Translational andrology and urology, 15(2), 32. https://doi.org/10.21037/tau-2025-729
MLA
de Souza VPB, et al.. "Immunotherapy in metastatic castration-resistant prostate cancer: transformative for the few, not for all.." Translational andrology and urology, vol. 15, no. 2, 2026, pp. 32.
PMID
41809806 ↗
🏷️ 키워드 / MeSH 📖 같은 키워드 OA만
🏷️ 같은 키워드 · 무료전문 — 이 논문 MeSH/keyword 기반
- PARP Inhibition in Prostate Cancer: Current Status, Resistance Mechanisms, and Clinical Challenges.
- Insights from PSMAfore: impact on health-related quality of life.
- Rethinking combination strategies in metastatic castration-resistant prostate cancer (mCRPC)-lessons from KEYNOTE-641.
- Pembrolizumab for high TMB castration-resistant prostate cancer: A precision medicine case report.
- Continuing Immunotherapy Beyond Progression Prolongs the Survival of Patients With Extensive-Stage Small-Cell Lung Cancer: A Multicenter Retrospective Analysis.
- genetic testing and treatment patterns for patients with HER2-negative early-stage breast cancer in the US community setting.